豹皮樟总黄酮治疗2型糖尿病大鼠模型的机制研究
|
摘要
目的研究豹皮樟总黄酮(TFLC,Total Flavonoids of Litsea Coreana)对实验性2型糖尿病大鼠模型的治疗作用及部分机制。
方法以改良的造模方法建立2型糖尿病大鼠模型,用口服葡萄糖耐量实验(OGTT)和测定空腹血糖和血胰岛素水平来评价模型是否成功建立,然后将成模大鼠分为模型组和治疗组,治疗组以非诺贝特和吡咯列酮作为阳性对照药,分别采用大、小剂量的TFLC治疗6周,同时设立正常对照组和高脂对照组,治疗结束时进行OGTT和胰岛素耐量实验(ITT)。将所有大鼠处死后,留取大鼠血清测定各项生化指标,留取肝脏组织做油红染色观察脂肪的聚集,提取肝脏的总RNA进行RT Realtime-PCR检测2型糖尿病相关基因PTP1B的mRNA水平表达,留取胰腺做胰岛素的免疫组化分析和促凋亡基因Bak1的mRNA水平表达,Western Blot检测大鼠骨骼肌中PTP1B的蛋白水平表达。
结果口服葡萄糖耐量实验和胰岛素敏感指数(ISI)证实改良的造模方法已成功地建立了2型糖尿病大鼠模型,且模型组的体重、尿液葡萄糖含量都显著高于对照组。用药治疗后,治疗组大鼠的多个血清生化指标,如空腹血糖(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(Fins)、ISI、甘油三酯(TG)、总胆固醇(TC)等均显著降低。肝脏组织切片的油红染色结果显示治疗组与模型组及高脂对照组相比,脂滴的数目和大小均明显减少。RT Realtime-PCR结果显示模型组PTP1BmRNA水平显著升高,治疗组PTP1B mRNA水平的表达与模型组相比显著降低。模型组胰腺组织的胰岛面积显著小于对照组,相对应地,Bak1基因表达增加,而TFLC可部分恢复减小的胰岛面积,减少Bak1基因的表达。骨骼肌的WesternBlot检测显示与模型组相比,大剂量TFLC治疗组PTP1B的表达可显著降低。
结论TFLC具有明显的降脂降糖效应,其作用可能与其促进胰岛的增生,减少胰腺的凋亡,降低肝脏和骨骼肌中PTP1B在mRNA水平和蛋白质水平的表达,进而提高胰岛素的敏感性有关。
Objective: To explore the effects and part mechanism of action of TFLC on experimental T2DM rat model.
Method: We established type 2 diabetes mellitus rat model in an improved method. With oral glucose tolerance test (OGTT) and determination of fasting blood glucose and blood insulin levels ,the model was assessed whether established successfully. These rat models were then randomly allocated into model group and treatment group which contained Fenofibrate and Pioglitazone as positive controls. It also contained large dose and small dose of TFLC which were fed 6 weeks for therapy. At the same time, we set up normal control group and high fat control group. At the end of treatment, we did OGTT and insulin tolerance test(ITT). As all rats were sacrificed, blood serum of rats were taken to detect kinds of biochemical indices; liver tissues were kept to carry out dyeing of oil red O to survey the accumulation of fat and messenger RNA was extracted from liver tissues to proceed Realtime-PCR experiments to explore the expression of PTP1B, a related gene of type 2 diabetes mellitus ; pancreatic tissues were obtained to do immunohistochemical analysis;skeletal muscles were used to analyze the expression of PTP1B by Western Blot.
Result: The OGTT and insulin sensitivity index(ISI) indicateed that type 2 diabetes mellitus rat model was established successfully in an improved method. Body weights and glucose in urine of T2DM model group are higher than normal control group. After medicating, several serum index of rats in treatment group were significantly decreased, such as fasting blood glucose(FBG), glycosylated hemoglobin(HbA1c),fasting insulin(Fins),ISI, triglyceride(TG), total cholesterol(TC) and so on. It was suggested the enhancement of insulin sensitivity. Staining on liver tissue slices with oil red O showed a significant reduction of lipid droplet in treatment groups, compared with T2DM group and high fat control group. Results of RT Realtime-PCR displayed that mRNA of PTP1B in model group increased significantly and mRNA of PTP1B in treatment groups were decreased significantly compared to T2DM group. Pancreatic islet area in model group was much smaller than in normal control. Consistent with this, gene Bak1 was expressed higher in model group. However, pancreatic islet area could be partially restored and expression of Bak1 could be inhibited by TFLC. Detection of Western Blot of skeletal muscles indicates a notable reduction of PTP1B expressions in large dose of TFLC treatment group compared to T2DM group.
Conclusion:TFLC could reduce blood fat and glucose apparently. Its role may be related to the proliferation of pancreatic islets, the reduction of apoptosis in pancreas, decrease of PTP1B in mRNA and protein levels, and then enhancement of insulin sensitivity.
方法以改良的造模方法建立2型糖尿病大鼠模型,用口服葡萄糖耐量实验(OGTT)和测定空腹血糖和血胰岛素水平来评价模型是否成功建立,然后将成模大鼠分为模型组和治疗组,治疗组以非诺贝特和吡咯列酮作为阳性对照药,分别采用大、小剂量的TFLC治疗6周,同时设立正常对照组和高脂对照组,治疗结束时进行OGTT和胰岛素耐量实验(ITT)。将所有大鼠处死后,留取大鼠血清测定各项生化指标,留取肝脏组织做油红染色观察脂肪的聚集,提取肝脏的总RNA进行RT Realtime-PCR检测2型糖尿病相关基因PTP1B的mRNA水平表达,留取胰腺做胰岛素的免疫组化分析和促凋亡基因Bak1的mRNA水平表达,Western Blot检测大鼠骨骼肌中PTP1B的蛋白水平表达。
结果口服葡萄糖耐量实验和胰岛素敏感指数(ISI)证实改良的造模方法已成功地建立了2型糖尿病大鼠模型,且模型组的体重、尿液葡萄糖含量都显著高于对照组。用药治疗后,治疗组大鼠的多个血清生化指标,如空腹血糖(FBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(Fins)、ISI、甘油三酯(TG)、总胆固醇(TC)等均显著降低。肝脏组织切片的油红染色结果显示治疗组与模型组及高脂对照组相比,脂滴的数目和大小均明显减少。RT Realtime-PCR结果显示模型组PTP1BmRNA水平显著升高,治疗组PTP1B mRNA水平的表达与模型组相比显著降低。模型组胰腺组织的胰岛面积显著小于对照组,相对应地,Bak1基因表达增加,而TFLC可部分恢复减小的胰岛面积,减少Bak1基因的表达。骨骼肌的WesternBlot检测显示与模型组相比,大剂量TFLC治疗组PTP1B的表达可显著降低。
结论TFLC具有明显的降脂降糖效应,其作用可能与其促进胰岛的增生,减少胰腺的凋亡,降低肝脏和骨骼肌中PTP1B在mRNA水平和蛋白质水平的表达,进而提高胰岛素的敏感性有关。
Objective: To explore the effects and part mechanism of action of TFLC on experimental T2DM rat model.
Method: We established type 2 diabetes mellitus rat model in an improved method. With oral glucose tolerance test (OGTT) and determination of fasting blood glucose and blood insulin levels ,the model was assessed whether established successfully. These rat models were then randomly allocated into model group and treatment group which contained Fenofibrate and Pioglitazone as positive controls. It also contained large dose and small dose of TFLC which were fed 6 weeks for therapy. At the same time, we set up normal control group and high fat control group. At the end of treatment, we did OGTT and insulin tolerance test(ITT). As all rats were sacrificed, blood serum of rats were taken to detect kinds of biochemical indices; liver tissues were kept to carry out dyeing of oil red O to survey the accumulation of fat and messenger RNA was extracted from liver tissues to proceed Realtime-PCR experiments to explore the expression of PTP1B, a related gene of type 2 diabetes mellitus ; pancreatic tissues were obtained to do immunohistochemical analysis;skeletal muscles were used to analyze the expression of PTP1B by Western Blot.
Result: The OGTT and insulin sensitivity index(ISI) indicateed that type 2 diabetes mellitus rat model was established successfully in an improved method. Body weights and glucose in urine of T2DM model group are higher than normal control group. After medicating, several serum index of rats in treatment group were significantly decreased, such as fasting blood glucose(FBG), glycosylated hemoglobin(HbA1c),fasting insulin(Fins),ISI, triglyceride(TG), total cholesterol(TC) and so on. It was suggested the enhancement of insulin sensitivity. Staining on liver tissue slices with oil red O showed a significant reduction of lipid droplet in treatment groups, compared with T2DM group and high fat control group. Results of RT Realtime-PCR displayed that mRNA of PTP1B in model group increased significantly and mRNA of PTP1B in treatment groups were decreased significantly compared to T2DM group. Pancreatic islet area in model group was much smaller than in normal control. Consistent with this, gene Bak1 was expressed higher in model group. However, pancreatic islet area could be partially restored and expression of Bak1 could be inhibited by TFLC. Detection of Western Blot of skeletal muscles indicates a notable reduction of PTP1B expressions in large dose of TFLC treatment group compared to T2DM group.
Conclusion:TFLC could reduce blood fat and glucose apparently. Its role may be related to the proliferation of pancreatic islets, the reduction of apoptosis in pancreas, decrease of PTP1B in mRNA and protein levels, and then enhancement of insulin sensitivity.
引文
1.周军,张志健,雷小宝。2型糖尿病的研究进展[J]。邯郸医学高等专科学校学报,2005,18(4):356-258.
2.吴家睿。2型糖尿病发生发展的分子机制研究[J]。生命科学,2006,18(5):411-413.
3. Wild S, Roqlic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5):1047-1053.
4. KahnSE. Theimportanceof b-cellfailureinthedevelopment and progression of type 2 diabetes. JClinEndocrinolMetab,2001, 86(9): 4047-4058.
5. VialettesB, ValeroR. Earlystagesof b-celldeficiency: the anticipated chronicle to type
2 diabetes. Diabetes Metab,2003, 29 (2 Pt 3): S11-15.
6.陈玉璞,程文明,李俊。老鹰茶中黄酮类化学成分分析[J]。安徽医科大学学报,2008,43(1):65-67.
7.陈琳,程文明等。豹皮樟总黄酮抗炎作用及部分机制研究[J]。安徽医科大学学报,2004,39(6):439-442.
8.刘锦红.老鹰茶对小鼠血糖和血脂的影响观察[J].中华实用中西医杂志,2003,3(16)14:2057-8.
9.陈琳,程文明,胡成穆等.豹皮樟总黄酮抗炎作用及部分机制研究[J].安徽医科大学学报,2004,39(6):439-42.
10.倪鸿昌,李俊,金涌,等.豹皮樟总黄酮对大鼠非酒精性脂肪性肝炎的防治作用[J].中国药理学通报2006,22(5):591-4.
11.吕雄文,李俊等。老鹰茶总黄酮降血糖作用的实验研究[J]。中国中医药科技,2008,15(2):119-121.
12.孙玉秀,鲁云霞,汪凌云等。豹皮樟总黄酮降低2型糖尿病大鼠血糖的可能机制研究[J]。中国中西医结合杂志,2010,30(6):617-621.
13.鲁云霞,孙玉秀,汪凌云等。重组人PTP1B的原核高效表达及TFLC的体外抑制剂实验[J]。中国医药生物技术,2009,4(3):212-218.
14.郭啸华,刘志红等。实验性2型糖尿病大鼠模型的建立[J]。肾脏病与透析肾移植杂志,2000,9(4):351-355.
15.张汝学,贾正平等。实验性2型糖尿病大鼠模型的建立和评价(I)—体重、血糖和肝糖原的变化[J]。西北国防医学杂志,2007,28(3):161-163.
16.周斌,蒋晓真,顾哲。吡格列酮对合并代谢综合征的2型糖尿病患者血清炎症因子及胰岛素抵抗的影响[J]。实用医学杂志,2010,26(2):305-307.
17.李蓉。二甲双胍联合吡格列酮在治疗肥胖2型糖尿病患者中的应用[J]。四川医学,2009,30(12):1930-1.
18.梁莉,张春霞。吡格列酮改善糖尿病前期胰岛素抵抗的研究[J]。吉林医学,2010,31(23):3855-6.
19.杨文英。2008年糖尿病研究进展[J]。医学研究杂志,2009,38(8):3-4.
20.边德志,张帆等。罗格列酮非诺贝特对高血糖高甘油三酯血症患者体脂血压和胰岛素敏感性的影响[J]。济宁医学院学报,2009,32(2):100-102.
21.李荣春,冯凭。非诺贝特对IGT合并高三酰甘油血症人群的胰岛素敏感性和胰岛β细胞分泌功能的影响[J]。天津医药,2008,36(12):968-970.
22.王文平,王佑民,王丽萍。非诺贝特和吡格列酮对肥胖大鼠血清内脏脂肪素的影响[J]。中国糖尿病杂志,2009,17(3):228-230.
23.孙红,宋波等。消渴欣胶囊降血糖作用研究[J]。中药药理与临床,2005,21(1):37.
24.冼苏。糖尿病肝病的研究现状及进展[J]。广西医学,2004,26(7):918-920.
25.张薇,李静雅,李佳。糖尿病和肥胖症治疗新靶点PTP1B抑制剂的研究进展[J]。生命科学,2006,18(5):462-466.
1.吴家睿。2型糖尿病发生发展的分子机制研究[J]。生命科学,2006,18(5):411-413.
2. Himsworth H P. Diabetes mellitus: its differentiation into insulin sensitive and insulin insensitive types[J]. Lancet, 1936,1:127-130.
3.谢利芳,许志华,郭凯霞。2型糖尿病胰岛素抵抗研究进展[J]。科学技术与工程,2010,10(15):3664-3669.
4. Gum RJ,Gaede LL,Koterski SL, et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice[J]. Diabetes,2003,52:21-28.
5. Xue B,Kim YB, Lee A, et al. Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance[J]. J Biol Chem, 2007,282:23829-23840.
6. Maciej T, Malecki, Tomasz Klupa. Type 2 diabetes mellitus: from genes to disease[J]. Pharmacological Reports. 2005,57:20-32.
7. Arfa I, Abid A, Malouche D, et al. Familial aggregation and excess maternal transmission of type 2 diabetes in Tunisia[J]. Postgrad Med J. 2007,83(979):348-351.
8.周莉,孙子林。2型糖尿病病因研究进展[J]。实用糖尿病杂志,2007,4(2):56-57.
9.刘小红。PTP-1B及其抑制剂与2型糖尿病的研究现状[J]。天津药学,2008,20(1):68-71.
10.鲁云霞,李俊。蛋白酪氨酸磷酸酶1B的研究进展[J]。实用糖尿病杂志,2007,4(2):54-56.
11.邹大进。蛋白酪氨酸磷酸酶1B与代谢综合征[J]。国外医学内分泌分册,2005,25(3):148-150.
12. Heinonen KM, Tremblay ML. Protein tyrosine phosphatase 1B hematopoiesis[J]. Cell Cycle, 2006,5:1053-6.
13.马宁,刘素筠,冯艳凌。蛋白酪氨酸磷酸酶1B与细胞信号转导[J]。2008,28(S):10-13.
14. Klama L D, Boss O, Peroni O D, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein tyrosine phosphatase
1B-deficient mice[J]. Mol Cell Biol, 2000,20:5479.
15. Haj F G, Zabolotny JM, Kim Y B, et al. Liver-specific protein-tyrosine phosphatase 1B(PTP-1B) re-expression alters glucose homeostasis of PTP-1B mice[J]. J Biol Chem, 2005,280:15038.
16. Kushner J, Haj FG, Klaman L D, et al. Islet-sparing effects of protein tyrosine phosphatase-1B deficiency delays onset of diabetes in InsRS2 knockout mice[J]. Diabetes, 2004,53:61.
17. Di Paola R, Frittitta L,MscioG, et al. Avariation in 3-prime UTR of hPTP1B increases specific gene expression and associates with insulin resisitance[J]. Am J Hum Genet, 2002,70:806-812.
18. Abroad F,Considine R V,Baoer T L,et al.Improved Se nsitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatase in adipose tissue[J]. Metabolism,1997,46:(10).1140-1145.
19. Cheng A,Vetani N,Simoncic P D,Chaubey V P,Lee-Loy A,McGlade C J,Kennedy B tP,Tremblay M L Atten nuation of leptin action and regulation of obesity byprotein tyrosine phosphatase 1B[J].Dev Ce ll,2002,2(4):497- 503.
20. Zabolotry J M,Bence-Hanulec K K,Stricker-Krongrad A,et al.PTP1B regulates leptin signal transduction in vivo[J].Dev Ce ll,2002,2(4):489-495.
21. Cook WS,Unger RH. Protein tyrosine phosphatase 1B:a potentialleptin esistance factor of obesity[J].Dev Cell,2002,2(4):385-387.
22. Lam NT,Covey SD,Lewis JT,et al. Leptin resistance following over-expression Of protein tyrosine phosphatase 1B in liver[J]. J MOI Endocrinol,2006,36:163-174.
23. Murthy V S,Kulkarm V M.Molecular modelmg of protein tyrosine phosphatase 1B(PTP-1B) inhibitors[J].Bioorg Med Chem,2002,10(4):897.
24. Johnson T O, Ermolieff J, Jirouesk M R. Protein tyrosine phosphatase 1B inhibitors for diabetes[J]. Nat Rev Drug discov, 2002, 1(9): 696-709.
25. Xie L P, Zhang Z Y, Andersen, et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling[J]. Biochemistry, 2003, 42 (44): 12792-12804.
26. Wiesmann C, Barr K J, Kung J, et al. Allosteric inhibition of protein tyrosine phosphatase 1B[J]. Nat Struc Mol Biol, 2004,11(8): 730-737.
27. Hansen S K, Erlanson M T, Shiau T P, et al. Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue. Biochemistry[J]. 2005, 44(21):7704-7712.
28. LiuG. Technologyevaluation: ISIS-113715, Isis[J]. CurrOpinMol Ther, 2004, 6(3): 331-336.
29.王辰,王沥,杨泽。蛋白质酪氨酸磷酸酶1B(PTP1B)与2型糖尿病及肥胖的关系[J]。遗传,2004,26(6):941-946.
2.吴家睿。2型糖尿病发生发展的分子机制研究[J]。生命科学,2006,18(5):411-413.
3. Wild S, Roqlic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004, 27(5):1047-1053.
4. KahnSE. Theimportanceof b-cellfailureinthedevelopment and progression of type 2 diabetes. JClinEndocrinolMetab,2001, 86(9): 4047-4058.
5. VialettesB, ValeroR. Earlystagesof b-celldeficiency: the anticipated chronicle to type
2 diabetes. Diabetes Metab,2003, 29 (2 Pt 3): S11-15.
6.陈玉璞,程文明,李俊。老鹰茶中黄酮类化学成分分析[J]。安徽医科大学学报,2008,43(1):65-67.
7.陈琳,程文明等。豹皮樟总黄酮抗炎作用及部分机制研究[J]。安徽医科大学学报,2004,39(6):439-442.
8.刘锦红.老鹰茶对小鼠血糖和血脂的影响观察[J].中华实用中西医杂志,2003,3(16)14:2057-8.
9.陈琳,程文明,胡成穆等.豹皮樟总黄酮抗炎作用及部分机制研究[J].安徽医科大学学报,2004,39(6):439-42.
10.倪鸿昌,李俊,金涌,等.豹皮樟总黄酮对大鼠非酒精性脂肪性肝炎的防治作用[J].中国药理学通报2006,22(5):591-4.
11.吕雄文,李俊等。老鹰茶总黄酮降血糖作用的实验研究[J]。中国中医药科技,2008,15(2):119-121.
12.孙玉秀,鲁云霞,汪凌云等。豹皮樟总黄酮降低2型糖尿病大鼠血糖的可能机制研究[J]。中国中西医结合杂志,2010,30(6):617-621.
13.鲁云霞,孙玉秀,汪凌云等。重组人PTP1B的原核高效表达及TFLC的体外抑制剂实验[J]。中国医药生物技术,2009,4(3):212-218.
14.郭啸华,刘志红等。实验性2型糖尿病大鼠模型的建立[J]。肾脏病与透析肾移植杂志,2000,9(4):351-355.
15.张汝学,贾正平等。实验性2型糖尿病大鼠模型的建立和评价(I)—体重、血糖和肝糖原的变化[J]。西北国防医学杂志,2007,28(3):161-163.
16.周斌,蒋晓真,顾哲。吡格列酮对合并代谢综合征的2型糖尿病患者血清炎症因子及胰岛素抵抗的影响[J]。实用医学杂志,2010,26(2):305-307.
17.李蓉。二甲双胍联合吡格列酮在治疗肥胖2型糖尿病患者中的应用[J]。四川医学,2009,30(12):1930-1.
18.梁莉,张春霞。吡格列酮改善糖尿病前期胰岛素抵抗的研究[J]。吉林医学,2010,31(23):3855-6.
19.杨文英。2008年糖尿病研究进展[J]。医学研究杂志,2009,38(8):3-4.
20.边德志,张帆等。罗格列酮非诺贝特对高血糖高甘油三酯血症患者体脂血压和胰岛素敏感性的影响[J]。济宁医学院学报,2009,32(2):100-102.
21.李荣春,冯凭。非诺贝特对IGT合并高三酰甘油血症人群的胰岛素敏感性和胰岛β细胞分泌功能的影响[J]。天津医药,2008,36(12):968-970.
22.王文平,王佑民,王丽萍。非诺贝特和吡格列酮对肥胖大鼠血清内脏脂肪素的影响[J]。中国糖尿病杂志,2009,17(3):228-230.
23.孙红,宋波等。消渴欣胶囊降血糖作用研究[J]。中药药理与临床,2005,21(1):37.
24.冼苏。糖尿病肝病的研究现状及进展[J]。广西医学,2004,26(7):918-920.
25.张薇,李静雅,李佳。糖尿病和肥胖症治疗新靶点PTP1B抑制剂的研究进展[J]。生命科学,2006,18(5):462-466.
1.吴家睿。2型糖尿病发生发展的分子机制研究[J]。生命科学,2006,18(5):411-413.
2. Himsworth H P. Diabetes mellitus: its differentiation into insulin sensitive and insulin insensitive types[J]. Lancet, 1936,1:127-130.
3.谢利芳,许志华,郭凯霞。2型糖尿病胰岛素抵抗研究进展[J]。科学技术与工程,2010,10(15):3664-3669.
4. Gum RJ,Gaede LL,Koterski SL, et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice[J]. Diabetes,2003,52:21-28.
5. Xue B,Kim YB, Lee A, et al. Protein-tyrosine phosphatase 1B deficiency reduces insulin resistance and the diabetic phenotype in mice with polygenic insulin resistance[J]. J Biol Chem, 2007,282:23829-23840.
6. Maciej T, Malecki, Tomasz Klupa. Type 2 diabetes mellitus: from genes to disease[J]. Pharmacological Reports. 2005,57:20-32.
7. Arfa I, Abid A, Malouche D, et al. Familial aggregation and excess maternal transmission of type 2 diabetes in Tunisia[J]. Postgrad Med J. 2007,83(979):348-351.
8.周莉,孙子林。2型糖尿病病因研究进展[J]。实用糖尿病杂志,2007,4(2):56-57.
9.刘小红。PTP-1B及其抑制剂与2型糖尿病的研究现状[J]。天津药学,2008,20(1):68-71.
10.鲁云霞,李俊。蛋白酪氨酸磷酸酶1B的研究进展[J]。实用糖尿病杂志,2007,4(2):54-56.
11.邹大进。蛋白酪氨酸磷酸酶1B与代谢综合征[J]。国外医学内分泌分册,2005,25(3):148-150.
12. Heinonen KM, Tremblay ML. Protein tyrosine phosphatase 1B hematopoiesis[J]. Cell Cycle, 2006,5:1053-6.
13.马宁,刘素筠,冯艳凌。蛋白酪氨酸磷酸酶1B与细胞信号转导[J]。2008,28(S):10-13.
14. Klama L D, Boss O, Peroni O D, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein tyrosine phosphatase
1B-deficient mice[J]. Mol Cell Biol, 2000,20:5479.
15. Haj F G, Zabolotny JM, Kim Y B, et al. Liver-specific protein-tyrosine phosphatase 1B(PTP-1B) re-expression alters glucose homeostasis of PTP-1B mice[J]. J Biol Chem, 2005,280:15038.
16. Kushner J, Haj FG, Klaman L D, et al. Islet-sparing effects of protein tyrosine phosphatase-1B deficiency delays onset of diabetes in InsRS2 knockout mice[J]. Diabetes, 2004,53:61.
17. Di Paola R, Frittitta L,MscioG, et al. Avariation in 3-prime UTR of hPTP1B increases specific gene expression and associates with insulin resisitance[J]. Am J Hum Genet, 2002,70:806-812.
18. Abroad F,Considine R V,Baoer T L,et al.Improved Se nsitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatase in adipose tissue[J]. Metabolism,1997,46:(10).1140-1145.
19. Cheng A,Vetani N,Simoncic P D,Chaubey V P,Lee-Loy A,McGlade C J,Kennedy B tP,Tremblay M L Atten nuation of leptin action and regulation of obesity byprotein tyrosine phosphatase 1B[J].Dev Ce ll,2002,2(4):497- 503.
20. Zabolotry J M,Bence-Hanulec K K,Stricker-Krongrad A,et al.PTP1B regulates leptin signal transduction in vivo[J].Dev Ce ll,2002,2(4):489-495.
21. Cook WS,Unger RH. Protein tyrosine phosphatase 1B:a potentialleptin esistance factor of obesity[J].Dev Cell,2002,2(4):385-387.
22. Lam NT,Covey SD,Lewis JT,et al. Leptin resistance following over-expression Of protein tyrosine phosphatase 1B in liver[J]. J MOI Endocrinol,2006,36:163-174.
23. Murthy V S,Kulkarm V M.Molecular modelmg of protein tyrosine phosphatase 1B(PTP-1B) inhibitors[J].Bioorg Med Chem,2002,10(4):897.
24. Johnson T O, Ermolieff J, Jirouesk M R. Protein tyrosine phosphatase 1B inhibitors for diabetes[J]. Nat Rev Drug discov, 2002, 1(9): 696-709.
25. Xie L P, Zhang Z Y, Andersen, et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling[J]. Biochemistry, 2003, 42 (44): 12792-12804.
26. Wiesmann C, Barr K J, Kung J, et al. Allosteric inhibition of protein tyrosine phosphatase 1B[J]. Nat Struc Mol Biol, 2004,11(8): 730-737.
27. Hansen S K, Erlanson M T, Shiau T P, et al. Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue. Biochemistry[J]. 2005, 44(21):7704-7712.
28. LiuG. Technologyevaluation: ISIS-113715, Isis[J]. CurrOpinMol Ther, 2004, 6(3): 331-336.
29.王辰,王沥,杨泽。蛋白质酪氨酸磷酸酶1B(PTP1B)与2型糖尿病及肥胖的关系[J]。遗传,2004,26(6):941-946.